{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:10:41Z","timestamp":1795057841507,"version":"4.10.2"},"reference-count":45,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Infections remain a challenge during treatment of patients with multiple myeloma (MM) with anti\u2013B-cell maturation antigen (BCMA) and anti\u2013G protein-coupled receptor class C group 5 member D (GPRC5D) bispecific antibodies (bsAbs). However, the mechanism underlying different rates and severity of infections induced by the 2 bsAbs remains poorly understood. Single-cell RNA sequencing of bone marrow (BM) aspirates of 11 patients with MM and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. GPRC5D expression was restricted to malignant and less to normal plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted BM mature B cells, from 4.9% to 0% (P&amp;lt; .001), and normal PCs, from 0.17% to &amp;lt;0.0002% (P&amp;lt; .001), during treatment of 62 patients with relapsed MM. This was observed throughout therapy. Additional flow cytometry (n = 31) and single-cell RNA sequencing studies (n = 8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIc\u03b31 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, confirming no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that although GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onward. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and supports individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B-cell malignancies or autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029572","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:18:01Z","timestamp":1765984681000},"page":"1070-1082","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-9253","authenticated-orcid":false,"given":"Tomas","family":"Jelinek","sequence":"first","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"},{"name":"3Sylvester Comprehensive Cancer Center, Myeloma Research Institute, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-0773","authenticated-orcid":false,"given":"David","family":"Zihala","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"},{"name":"4Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-3040","authenticated-orcid":false,"given":"Aintzane","family":"Zabaleta","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1152-6959","authenticated-orcid":false,"given":"Ioannis V.","family":"Kostopoulos","sequence":"additional","affiliation":[{"name":"6Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-4200","authenticated-orcid":false,"given":"Ondrej","family":"Soucek","sequence":"additional","affiliation":[{"name":"7Department of Immunology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Venglar","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Moreno","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"8Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3066-8290","authenticated-orcid":false,"given":"Eva","family":"Radova","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-0992","authenticated-orcid":false,"given":"Luis Esteban","family":"Tamariz-Amador","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-0351","authenticated-orcid":false,"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[{"name":"8Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8589-1577","authenticated-orcid":false,"given":"Ludmila","family":"Muronova","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Manubens","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania","family":"Tsitsilonis","sequence":"additional","affiliation":[{"name":"6Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5885-4218","authenticated-orcid":false,"given":"Tereza","family":"Popkova","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3074-9229","authenticated-orcid":false,"given":"Carmen","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-6966","authenticated-orcid":false,"given":"Anjana","family":"Anilkumar Sithara","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"},{"name":"4Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Corrado","sequence":"additional","affiliation":[{"name":"9Center for Early Detection and Interception, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayda","family":"Bidikian","sequence":"additional","affiliation":[{"name":"9Center for Early Detection and Interception, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-5140","authenticated-orcid":false,"given":"Camila","family":"Guerrero","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-5667","authenticated-orcid":false,"given":"Veronika","family":"Kapustova","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1686-0587","authenticated-orcid":false,"given":"Daniel","family":"Bilek","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"},{"name":"4Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Hagner","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Larrayoz","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Martinez Climent","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1523-2981","authenticated-orcid":false,"given":"Lucie","family":"Broskevicova","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-7873","authenticated-orcid":false,"given":"Jana","family":"Mihalyova","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[{"name":"11Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-0106","authenticated-orcid":false,"given":"Tereza","family":"Sevcikova","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"},{"name":"4Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"9Center for Early Detection and Interception, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San Miguel","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"12Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"13Department of Medicine, Korea University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Radocha","sequence":"additional","affiliation":[{"name":"14Fourth Department of Internal Medicine-Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"8Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"5Cancer Center Clinica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[{"name":"1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"2Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"24","key":"2026030511215986800_bib1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2026030511215986800_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026030511215986800_bib3","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 magnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"22","key":"2026030511215986800_bib4","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026030511215986800_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2026030511215986800_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"19","key":"2026030511215986800_bib7","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026030511215986800_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"issue":"13","key":"2026030511215986800_bib9","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2026030511215986800_bib10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"4","key":"2026030511215986800_bib11","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (monumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"22","key":"2026030511215986800_bib12","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/bloodadvances.2025016613","article-title":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1","volume":"9","author":"Schinke","year":"2025","journal-title":"Blood Adv"},{"issue":"485","key":"2026030511215986800_bib13","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"2026030511215986800_bib14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"2026030511215986800_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma","volume":"145","author":"Eckmann","year":"2025","journal-title":"Blood"},{"issue":"25","key":"2026030511215986800_bib16","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non\u2013T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026030511215986800_bib17","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026030511215986800_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026030511215986800_bib19","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"2026030511215986800_bib20","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","article-title":"Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors","volume":"38","author":"Jelinek","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"2026030511215986800_bib21","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2026030511215986800_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/ejh.14316","article-title":"Real-world evidence on prognostic value of MRD in multiple myeloma using flow cytometry","volume":"114","author":"Muronova","year":"2025","journal-title":"Eur J Haematol"},{"issue":"25","key":"2026030511215986800_bib23","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2026030511215986800_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/cyto.a.24962","article-title":"40-Parameter\/37-color spectral cytometry panel for robust immunoprofiling of human lymphoid subsets in cancer patients","volume":"107","author":"Venglar","year":"2025","journal-title":"Cytom A"},{"key":"2026030511215986800_bib25","doi-asserted-by":"crossref","first-page":"112684","DOI":"10.1016\/j.jim.2019.112684","article-title":"Immunophenotypic dissection of normal hematopoiesis","volume":"475","author":"Orfao","year":"2019","journal-title":"J Immunol Methods"},{"key":"2026030511215986800_bib26","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3389\/fimmu.2019.02680","article-title":"Delineating human B cell precursor development with genetically identified PID cases as a model","volume":"10","author":"Wentink","year":"2019","journal-title":"Front Immunol"},{"issue":"0","key":"2026030511215986800_bib27","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1038\/bcj.2017.90","article-title":"Current applications of multiparameter flow cytometry in plasma cell disorders","volume":"7","author":"Jelinek","year":"2017","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026030511215986800_bib28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"2026030511215986800_bib29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2026030511215986800_bib30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2026030511215986800_bib31","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026030511215986800_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"26","key":"2026030511215986800_bib33","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1182\/blood.2024025643","article-title":"Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma","volume":"145","author":"Da Vi\u00e0","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026030511215986800_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026030511215986800_bib35","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026030511215986800_bib36","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026030511215986800_bib37","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2025.03.048","article-title":"Non-relapse mortality with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma","volume":"33","author":"Tix","year":"2025","journal-title":"Mol Ther"},{"issue":"18","key":"2026030511215986800_bib38","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"2026030511215986800_bib39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg Use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"2026030511215986800_bib40","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-Year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study [abstract]","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026030511215986800_bib41","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026030511215986800_bib42","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1182\/blood-2024-208192","article-title":"MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma [abstract]","volume":"144","author":"Prince","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026030511215986800_bib43","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1007\/s00277-025-06529-1","article-title":"De-escalated teclistamab dosing in relapsed\/refractory multiple myeloma: Czech myeloma group real-world evidence analysis","volume":"104","author":"Stork","year":"2025","journal-title":"Ann Hematol"},{"issue":"9","key":"2026030511215986800_bib44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune Disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2026030511215986800_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/2767-9764.CRC-22-0083","article-title":"Redirecting T-cell activity with anti-BCMA\/anti-CD3 bispecific antibodies in chronic lymphocytic leukemia and other B-cell lymphomas","volume":"2","author":"Martens","year":"2022","journal-title":"Cancer Res Commun"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/10\/1070\/2506872\/blood_bld-2025-029572-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/10\/1070\/2506872\/blood_bld-2025-029572-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:22:09Z","timestamp":1772727729000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/10\/1070\/557373\/Selective-B-cell-subset-depletion-underlies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029572","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,5]]},"published":{"date-parts":[[2026,3,5]]}}}